Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Risk factors

Topic: Risk, prevention and care in population studies

Plain-language summary

Approximately 2% of those aged ≥60 years had dementia, lower than published estimates. Dementia was higher in North Island; in 80- to 89-year-olds; among the Māori population when age-standardised, and 9% of all dementia cases had >1 dementia sub-type. To our knowledge, this is the first study ascertaining dementia estimates using NZ's whole-of-population IDI data. Estimates were lower than existing NZ estimates, for several reasons. Further work is required, including expanding IDI data sets, to develop future estimates that better reflect NZ's diverse population.

What this study adds

Evidence grade: Moderate

This study estimated that about 2% of people aged 60 and over in New Zealand had dementia, which is lower than previous estimates. It highlights the need for further work to improve future estimates, but it does not provide information on treating, curing, or preventing Alzheimer's disease.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Walesby, K. E., Exeter, D. J., Gibb, S., Wood, P. C., Starr, J. M., & Russ, T. C. (2020). Prevalence and geographical variation of dementia in New Zealand from 2012 to 2015: Brief report utilising routinely collected data within the Integrated Data Infrastructure. Australasian Journal on Ageing. https://doi.org/10.1111/ajag.12790

Vancouver

Walesby KE, Exeter DJ, Gibb S, Wood PC, Starr JM, Russ TC. Prevalence and geographical variation of dementia in New Zealand from 2012 to 2015: Brief report utilising routinely collected data within the Integrated Data Infrastructure. Australasian Journal on Ageing. 2020. doi:10.1111/ajag.12790. PMID: 32394527.

BibTeX

@article{walesby2020-32394527,
  author  = {Walesby, Katherine Elizabeth and Exeter, Daniel John and Gibb, Sheree and Wood, Philip C. and Starr, John M. and Russ, Tom C.},
  title   = {{Prevalence and geographical variation of dementia in New Zealand from 2012 to 2015: Brief report utilising routinely collected data within the Integrated Data Infrastructure}},
  journal = {Australasian Journal on Ageing},
  year    = {2020},
  doi     = {10.1111/ajag.12790},
  pmid    = {32394527},
  url     = {https://doi.org/10.1111/ajag.12790}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This study estimated that about 2% of people aged 60 and over in New Zealand had dementia, which is lower than previous estimates. It highlights the need for further work to improve future estimates, but it does not provide information on treating, curing, or preventing Alzheimer's disease.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 2 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 3 of 7; Citations per year 1 of 5; Impact for its field and year 2 of 6; Cited by studies here 0 of 6; Still being cited 1 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 45 of the 96 points it could be judged on, which is 47 of 100. Total 47 of 100.45 of the 96 points we could judge = 47 of 100

Published in a peer-reviewed journal, and it is a retrospective cohort study, reconstructed from past records. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, so that was left out: it earned 45 of the 96 points we could judge it on, which is 47 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Australasian Journal on Ageing)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 7 / 12 A retrospective cohort study, reconstructed from past records
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 2 / 5 2020 — within 10 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 3 / 7 Cited 17 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 2.1 citations a year over 8 year(s) since 2020
Impact for its field and year 2 / 6 Cited 1.1× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 1 / 4 Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Tom C. Russ: h-index 45 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Edinburgh: institution h-index 1,378 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 8 institution(s) in 2 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 32394527)
Free to read 2 / 2 Free to read
Points 45 / 96 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 45 of the 96 points we could judge it on is 47 out of 100.
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Risk factors from nearby years

Also tagged “prevalence”

1,224 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,224 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Risk factors

See all studies in Risk factors →